As a single mother, a new grandmother and emerging artist, Akaimi, 44, of San Antonio, TX, has an active and creative lifestyle. Her treatment for large granular lymphocytic leukemia was successful, and the cancer is now in remission, but she continues to have side effects from the chemo treatments. Her doctor recommended a biosimilar.
Not only did it work, but it saves me money too! Akaimi says.
My copay is only $25. Now I have the energy and extra money to attend my art exhibits, respond to my Instagram fans and care for my family.
Savings from biosimilars for patients like Akaimi are projected to grow to $100 billion by 2025.
View Akaimi and other patient stories in the 2021 Voices of Access report.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.